ÀϹݿ¬Á¦ : ºÎÀÎÁ¾¾çÇÐ |
- ÀϽà : 2015³â 9¿ù 18ÀÏ (±Ý)
- Àå¼Ò : ¿¡¸Þ¶öµåȦ B[3F] |
GO1-GO4 (08:20~09:00) |
ÁÂÀå : À̳«¿ì(°í·ÁÀÇ´ë) |
GO108:20~08:30 |
¼Õ±Ý¼± ¿¬¼¼ÀÇ´ë °³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Expanding Biospecimens from Korean Gynecologic Cancer Bank: Construction of Tissue Micro Arrays and Establishment of Immortalize Cell line. |
GO208:30~08:40 |
º¯½Â¿ø °¡Å縯ÀÇ´ë ÀÇÁ¤ºÎ¼º¸ðº´¿ø »êºÎÀΰú |
¾ÈÁ©¸®³ª Á¹¸®ÀÇ °áÁ¤ÀÌÈÄ BRCA mutation °Ë»ç ¹× ¿¹¹æÄ¡·á¿¡ ´ëÇÑ ÀνÄÁ¶»ç |
GO308:40~08:50 |
ÇÑ°æÈñ ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Residual ascites after neoadjuvant chemotherapy decreases treatment response and survival in patients with advanced-stage epithelial ovarian cancer |
GO408:50~09:00 |
±è¿µÅ ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
The role of re-exploration in uterine sarcoma found incidentally after initial surgery for presumed benign disease |
GO5-GO8 (09:00~09:40) |
ÁÂÀå : ¹®Çý¼º(ÀÌÈÀÇ´ë) |
GO509:00~09:10 |
±è¿µÅ ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
A scoring system to predict the risk of uterine sarcoma in patients with a uterine mass |
GO609:10~09:20 |
ÇãÀºÁø ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
IGFBP5-derived peptide as a novel angiogenesis inhibitor for treatment of ovarian cancer |
GO709:20~09:30 |
¹ÚÈ¿°æ ¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú |
Transvaginal ultrasound-guided biopsy of adnexal masses as a useful diagnostic alternative replacing
cytology or laparoscopy in advanced ovarian cancer patients |
GO809:30~09:40 |
¹éÀ̼± ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma |
GO9-GO12 (09:40~10:20) |
ÁÂÀå : ÀÌÁ¾ÇÐ(°æ»óÀÇ´ë) |
GO909:40~09:50 |
±è¼±¾Æ
|
The prevalence of HPV infection in the semen among Korean men and the effect of HPV infection on sperm parameters |
GO1009:50~10:00 |
ÀÌ»óÈÆ °í·ÁÀÇ´ë ¾È¾Ïº´¿ø »êºÎÀΰú |
Validation of an algorithm in Korean Women Ages 21-24 years with either Atypical Squamous Cells of Undetermined Significance or Low-grade Squamous Intraepithelial Lesion |
GO1110:00~10:10 |
À±°Ç ¾ç»êºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú |
Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine
cervical cancer |
GO1210:10~10:20 |
À¯¼ÒÀº
|
The risk factors and rate for progression of cervical intraepithelial lesions in HPV 16 or 18 infected women with ASCUS or LSIL: The Korean HPV cohort study. |
GO13-GO17 (10:50~11:40) |
ÁÂÀå : ±èÀçÈÆ(¿¬¼¼ÀÇ´ë) |
GO1310:50~11:00 |
±èÇöÁ¤ °Ç±¹´ëÇб³º´¿ø »êºÎÀΰú |
The impact of positive peritoneal cytology on prognosis in patients with cervical cancer: A meta-analysis |
GO1411:00~11:10 |
ÃÖÀ±Áø °¡Å縯ÀÇ´ë ¼¿ï¼º¸ðº´¿ø »êºÎÀΰú |
FROM CERVICAL INTRAEPITHELIAL NEOPLASIA TO CERVICAL SQUAMOUS CELL
CARCINOMA: AN INTEGRATIVE GENOMIC ANALYSIS |
GO1511:10~11:20 |
±èÅÂÈÆ ¿øÀÚ·ÂÀÇÇпø »êºÎÀΰú |
Outcome of salvage treatment for patients with recurrent cervical cancer; a single institutional
cohort study. |
GO1611:20~11:30 |
¼ÛÀçÀ± °í·ÁÀÇ´ë ¾È¾Ïº´¿ø »êºÎÀΰú |
Role of p16, p63, Ki67 in a two-tier system of low-grade and high-grade squamous intraepithelial lesion |
GO1711:30~11:40 |
¾ç¿ì°â ¿¬¼¼ÀÇ´ë °³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Application of oncothermia using LabEHY-100 inhibits the growth of ovarian and cervical cancer cells. |
GO18-GO21 (11:40~12:30) |
ÁÂÀå : ¹ÚÁø¿Ï(´Ü±¹ÀÇ´ë) |
GO1811:40~11:50 |
µ¿¸Þ¾Æ¸® °Ç±¹´ëÇб³º´¿ø »êºÎÀΰú |
Impact of surgical staging on prognosis in patients with borderline ovarian tumors: a meta-analysis |
GO1911:50~12:00 |
À±Á¤¿ø ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Role of diagnostic laparoscopy in advanced epithelial ovarian cancer : An experience at a
single institution |
GO2012:00~12:10 |
À±°¡¿µ ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú |
Expression of interactive genes associated with apoptosis and their prognostic value for ovarian carcinoma |
GO2112:10~12:20 |
Á¤À±Áö ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Identifying association between obesity and ovarian cancer based on SRA-1 gene over-expression |
GO22-GO24 (13:40~14:10) |
ÁÂÀå : °í¼®ºÀ(´ë±¸°¡Å縯ÀÇ´ë) |
GO2213:40~13:50 |
À̹æÇö ¼¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú |
Efficacy of On-Q Pain Relief System for Postoperative Pain Management in Gynecologic
Oncology Patients: A pilot study |
GO2313:50~14:00 |
±è¹Ì¼± ¼¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú |
Identifying risk factors for CT-based diagnosed post-lymphadenectomy lower-extremity lymphedema in patients with gynecologic cancers |
GO2414:00~14:10 |
½Å¼¼ÀÎ °¡Å縯ÀÇ´ë ¼¿ï¼º¸ðº´¿ø »êºÎÀΰú |
Transcriptome analysis reveals that Müllerian inhibiting substance regulates signaling pathways that contribue to endometrial carcinogenesis |
ÀϹݿ¬Á¦ : ºÎÀÎÁ¾¾çÇÐ |
- ÀϽà : 2015³â 9¿ù 18ÀÏ (±Ý)
- Àå¼Ò : ´ÙÀ̾ƸóµåȦ[3F] |
GO25-GO28 (15:10~15:50) |
ÁÂÀå : À̼±°æ(°æÈñÀÇ´ë) |
GO2515:10~15:20 |
¹ÚÁöÀº Ä¥°î°æºÏ´ëÇб³º´¿ø »êºÎÀΰú |
Prognostic value of F-18 PET metabolic parameters of regional lymph node in locally advanced cervical cancer patients treated with concurrent chemoradiotherapy |
GO2615:20~15:30 |
³²¼¼Çö ¼º±Õ°üÀÇ´ë °ºÏ»ï¼ºº´¿ø »êºÎÀΰú |
Efficacy of TachoSil¢ç in preventing hemorrhage after loop electrosurgical excision procedure |
GO2715:30~15:40 |
Á¤À¯¿¬ °¡Å縯ÀÇ´ë ¼ººó¼¾Æ®º´¿ø »êºÎÀΰú |
Clipping during distal external iliac lymphadenectomy increases lower leg lymphedema in patients with carcinoma of the cervix |
GO2815:40~15:50 |
µµ¾Æ¿µ ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Prognostic factors affected survival outcome of recurrent cervical cancer patients with pulmonary metastases without other organs involvement |
GO29-GO31 (15:50~16:20) |
ÁÂÀå : Á¤ÀºÈ¯(ÃæºÏÀÇ´ë) |
GO2915:50~16:00 |
À̵ÎÇà ¼º±Õ°üÀÇ´ë °ºÏ»ï¼ºº´¿ø »êºÎÀΰú |
Effect of menstrual phase on the surgical treatment of ovarian cyst |
GO3016:00~16:10 |
À̼¼¿¬ Â÷ÀÇ°úÇдëÇб³ ºÐ´çÂ÷º´¿ø »êºÎÀΰú |
Oncologic and obstetric outcomes of conservative surgery for borderline ovarian tumor at reproductive age |
GO3116:10~16:20 |
Á¤ÀºÁÖ ¿ï»ê´ëÇб³º´¿ø »êºÎÀΰú |
Frequency of a non-rising increase of serum CA-125 levels during chemotherapy treatment in recurrent patients of advanced epithelial ovarian cancer (EOC) after reviously being treated optimally |